Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020
![](/report_cover/8047/acute-lymphocytic-leukemia-all-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 72 - 96 Hours
DelveInsight’s, “Acute Lymphocytic Leukemia – Pipeline Insight, 2020,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute Lymphocytic Leukemia: Overview
Acute lymphocytic leukemia (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. 'Lymphocytic' means it develops from early (immature) forms of lymphocytes, a type of white blood cell.
ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.
Symptoms
The early signs and symptoms of ALL may be like the flu or other common diseases. Some of the commeon sign and symtoms are:
The following tests and procedures may be used:
Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as infection or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments will also be taken.
Complete blood count (CBC) with differential: A procedure in which a sample of blood is drawn and checked for the following:
Treatment
Four types of standard treatment are used for Acute Lymphocytic Leukemia:
This segment of the Acute Lymphocytic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Lymphocytic Leukemia Emerging Drugs
Further product details are provided in the report.
Acute Lymphocytic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different Acute Lymphocytic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
Acute Lymphocytic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Lymphocytic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Lymphocytic Leukemia drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acute Lymphocytic Leukemia – Pipeline Insight, 2020,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acute Lymphocytic Leukemia: Overview
Acute lymphocytic leukemia (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. 'Lymphocytic' means it develops from early (immature) forms of lymphocytes, a type of white blood cell.
ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to other parts of the body, including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles (in males). Some cancers can also start in these organs and then spread to the bone marrow, but these cancers are not leukemia.
Symptoms
The early signs and symptoms of ALL may be like the flu or other common diseases. Some of the commeon sign and symtoms are:
- Weakness or feeling tired.
- Fever or drenching night sweats.
- Easy bruising or bleeding.
- Petechiae (flat, pinpoint spots under the skin, caused by bleeding).
- Shortness of breath.
- Weight loss or loss of appetite.
- Pain in the bones or stomach.
- Pain or feeling of fullness below the ribs.
- Painless lumps in the neck, underarm, stomach, or groin.
- Having many infections.
The following tests and procedures may be used:
Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as infection or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments will also be taken.
Complete blood count (CBC) with differential: A procedure in which a sample of blood is drawn and checked for the following:
- The number of red blood cells and platelets.
- The number and type of white blood cells.
- The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.
- The portion of the blood sample made up of red blood cells.
Treatment
Four types of standard treatment are used for Acute Lymphocytic Leukemia:
- Chemotherapy: It is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Radiation therapy: Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing
- Chemotherapy with stem cell transplant: Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells
- Targeted therapy: Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapy may cause less harm to normal cells than chemotherapy or radiation therapy do.
This segment of the Acute Lymphocytic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Lymphocytic Leukemia Emerging Drugs
- CPX-351: Jazz Pharmaceuticals
- JZP-458: Jazz Pharmaceuticals
- UCART22: Cellectis
- JZP-341: Jazz Pharmaceuticals
Further product details are provided in the report.
Acute Lymphocytic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different Acute Lymphocytic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Lymphocytic Leukemia
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Acute Lymphocytic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Lymphocytic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Lymphocytic Leukemia drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia.
- In July 2016, Jazz Pharmaceuticals and Pfenex announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.
- In June 2018, Cellectis stated that the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a phase I clinical trial for UCART22
- Acute Lymphocytic Leukemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Lymphocytic Leukemia drugs?
- How many Acute Lymphocytic Leukemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Lymphocytic Leukemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Lymphocytic Leukemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Lymphocytic Leukemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- PersonGen BioTherapeutics
- Novartis Pharmaceuticals
- Jazz Pharmaceuticals
- Takara Bio Inc.
- Cellectis S.A.
- AbbVie
- Autolus Limited
- Juventas Cell Therapy Ltd.
- Pinze Lifetechnology Co. Ltd.
- Celgene
- CD7 CAR-T cells infusion
- CTL019
- JZP-458
- TBI-1501
- UCART22
- Navitoclax
- AUTO1
- CNCT19
- PZ01 CAR-T cells
- JCAR017
Introduction
Executive Summary
Acute Lymphocytic Leukemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute Lymphocytic Leukemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Lymphocytic Leukemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Lymphocytic Leukemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and Phase II/III)
Comparative Analysis
JZP-458: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
CPX-351: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UCART22: Cellectis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
JZP-341: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Acute Lymphocytic Leukemia Key Companies
Acute Lymphocytic Leukemia Key Products
Acute Lymphocytic Leukemia- Unmet Needs
Acute Lymphocytic Leukemia- Market Drivers and Barriers
Acute Lymphocytic Leukemia- Future Perspectives and Conclusion
Acute Lymphocytic Leukemia Analyst Views
Acute Lymphocytic Leukemia Key Companies
Appendix
Executive Summary
Acute Lymphocytic Leukemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acute Lymphocytic Leukemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Lymphocytic Leukemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Lymphocytic Leukemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and Phase II/III)
Comparative Analysis
JZP-458: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
CPX-351: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UCART22: Cellectis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
JZP-341: Jazz Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Acute Lymphocytic Leukemia Key Companies
Acute Lymphocytic Leukemia Key Products
Acute Lymphocytic Leukemia- Unmet Needs
Acute Lymphocytic Leukemia- Market Drivers and Barriers
Acute Lymphocytic Leukemia- Future Perspectives and Conclusion
Acute Lymphocytic Leukemia Analyst Views
Acute Lymphocytic Leukemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acute Lymphocytic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acute Lymphocytic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acute Lymphocytic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acute Lymphocytic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products